The WHO states that 7 out of 100 patients in developed countries and 10 in 100 patients in developing countries acquire at least one hospital-acquired infection (HAI). Moreover, the Australian Institute of Health and Welfare (AIHW) states that 1,502 cases of hospital-associated Staphylococcus aureus bacteremia (SAB) were recorded in the public hospitals of Australia in 2016–2017. Likewise, the CDC estimates that around 1 in 31 patients in the U.S. contract at least one HAI at any given time.

Thus, the surging incidence of infections acquired in clinical settings will help the hospital-acquired infection diagnostics market exhibit rapid growth in the years to come. To diagnose HAIs accurately with a low turnaround time, medical device, life sciences, and biotechnology companies are focusing on the development of technologically advanced products. Essentially, diagnosing HAIs is no different from diagnosing other infections, and common techniques, such as urinalysis, immunoassays, and molecular diagnostics, are applied for detecting them.

Get More Insights: Hospital-Acquired Infection Diagnostics Market Revenue Estimation and Growth Forecast Report

Globally, the North American region will emerge as the leader of the hospital-acquired infection diagnostics market in the foreseeable future, owing to its improved healthcare sector, a surge in the number of patients affected by nosocomial infections, and a strong presence of prominent diagnostic product manufacturers in the U.S. and Canada. Additionally, the mounting geriatric population and soaring public awareness about HAIs will propel the use of such medical products.

Thus, the rising cases of HAIs and burgeoning geriatric population will facilitate the use of products to help diagnose them worldwide.